Bromide

Bromide

SCHEMBL829130

CCC[N+]1(C)CCOCC1.[Br-]

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1

The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CDC25A P30304 1/20 0.44
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
PABPC1 P11940 2/20 0.36
CTDSP1 Q9GZU7 2/20 0.35
CHRNB2 P17787 1/20 0.35
CHRNB4 P30926 1/20 0.35
CHRNA3 P32297 1/20 0.35
CHRNA7 P36544 1/20 0.35
CHRNA4 P43681 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
APOBEC3A P31941 2/20 0.34
APOBEC3G Q9HC16 2/20 0.34
THRB P10828 1/20 0.34
TERT O14746 7/20 0.33
USP2 O75604 1/20 0.31
GAA P10253 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL40079 0.97 CDC25A (0.45) CDC25AHPGDALOX15PABPC1CTDSP1
Iodide SCHEMBL30297486 0.95 CDC25A (0.44) CDC25AHPGDALOX15PABPC1CTDSP1
Hydrochloric Acid SCHEMBL15361368 0.95 CDC25A (0.44) CDC25AHPGDALOX15PABPC1CTDSP1
Water SCHEMBL15361295 0.95 CDC25A (0.44) CDC25AHPGDALOX15PABPC1CTDSP1
SCHEMBL18575589 0.91 CDC25A (0.41) CDC25AHPGDALOX15PABPC1CTDSP1
SCHEMBL1719164 0.89 CDC25A (0.41) CDC25AHPGDALOX15PABPC1CTDSP1
Bromide SCHEMBL2347777 0.86 CDC25A (0.49) CDC25AHPGDALOX15PABPC1CTDSP1
Bromide SCHEMBL3781155 0.84 CDC25A (0.51) CDC25AHPGDALOX15PABPC1CTDSP1
SCHEMBL9935792 0.84 HPGD (0.47) CDC25AHPGDALOX15PABPC1CTDSP1
SCHEMBL1491002 0.83 CDC25A (0.50) CDC25AHPGDALOX15PABPC1CTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089414-B1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION MERCK PATENT GMBH (DE) 2013-03-06 EP claimed
US-8143381-B2 Use of ionic liquids for membrane protein extraction MERCK PATENT GMBH (DE) 2012-03-27 US claimed
US-20100029917-A1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION MERCK PATENT GMBH (DE) 2010-02-04 US claimed
EP-3170789-B1 PRODUCTION PROCESS FOR FLUOROSULFONYLIMIDE AMMONIUM SALT NIPPON SODA CO (JP) 2018-04-18 EP disclosed
EP-3170789-A1 PRODUCTION PROCESS FOR FLUOROSULFONYLIMIDE SALT NIPPON SODA CO., LTD. (JP) 2017-05-24 EP disclosed
US-9242862-B2 Process for production of fluorosulfonylimide ammonium salt NIPPON SODA CO., LTD. (JP) 2016-01-26 US disclosed
US-9096502-B2 Production process for fluorosulfonylimide ammonium salt NIPPON SODA CO., LTD. (JP) 2015-08-04 US disclosed
EP-2674395-A1 PROCESS FOR PRODUCTION OF FLUOROSULFONYLIMIDE AMMONIUM SALT Nippon Soda Co., Ltd. (JP) 2013-12-18 EP disclosed
US-20130331609-A1 PRODUCTION PROCESS FOR FLUOROSULFONYLIMIDE AMMONIUM SALT NIPPON SODA CO., LTD. (JP) 2013-12-12 US disclosed
US-20130323154-A1 PROCESS FOR PRODUCTION OF FLUOROSULFONYLIMIDE AMMONIUM SALT NIPPON SODA CO., LTD. (JP) 2013-12-05 US disclosed
EP-2660196-A1 MANUFACTURING METHOD FOR FLUOROSULFONYLIMIDE AMMONIUM SALT Nippon Soda Co., Ltd. (JP) 2013-11-06 EP disclosed
EP-2089414-B1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION MERCK PATENT GMBH (DE) 2013-03-06 EP disclosed
US-8143381-B2 Use of ionic liquids for membrane protein extraction MERCK PATENT GMBH (DE) 2012-03-27 US disclosed
US-20100029917-A1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION MERCK PATENT GMBH (DE) 2010-02-04 US disclosed
EP-2089414-A1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION Merck Patent GmbH (DE) 2009-08-19 EP disclosed
WO-2008058604-A1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION MERCK PATENT GMBH (DE) 2008-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130331609-A1 PRODUCTION PROCESS FOR FLUOROSULFONYLIMIDE AMMONIUM SALT NPEPPS, DNPEP, FOS CDC25A 2308/4885HPGD 3509/4885ALOX15 4632/4885
US-20100029917-A1 USE OF IONIC LIQUIDS FOR MEMBRANE PROTEIN EXTRACTION APMAP, VAMP8, VAMP7 CDC25A 4145/4885HPGD 4350/4885ALOX15 4529/4885
US-20130323154-A1 PROCESS FOR PRODUCTION OF FLUOROSULFONYLIMIDE AMMONIUM SALT ASNS, NHERF1, NAAA CDC25A 2879/4885HPGD 3142/4885ALOX15 4575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.